Edition:
India

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.42USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
233,831
52-wk High
$3.93
52-wk Low
$2.20

Select another date:

Fri, Nov 17 2017

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

Select another date: